Shots:

• The agreement involves Astellas to pay an upfront payment of £85Mn to Quethera’s shareholder’s 
• Quethera uses recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells to treat glaucoma
• In pre-clinical models- this gene therapy improved survival rates of retinal ganglion cells (RGCs) in pre-clinical models

 Ref: Astellas | Image: Astellas